Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Gross Margin came in at 87.28% in Q1 2026, up 180.0% YoY from 31.17% in Q1 2025, and little changed on a QoQ basis from 87.24% in Q4 2025.
Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Gross Margin data on file, last reported at 87.28% in Q1 2026.
- Quarterly Gross Margin rose 180.0% year-over-year to 87.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85.89% (up 368.0% YoY) and the FY2025 annual result came in at 85.41%, up 355.0% from the prior year.
- Gross Margin held at 87.28% in Q1 2026, from 87.24% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 87.28% in Q1 2026 to a low of 71.58% in Q1 2022.
- A 5-year average of 82.52% and a median of 83.37% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin surged 1898 bps — and 2024, when it tumbled 808 bps.
- Tracing XERS's Gross Margin over 5 years: stood at 81.02% in 2022, then increased by 2 bps to 82.95% in 2023, then gained by 2 bps to 84.23% in 2024, then climbed by 4 bps to 87.24% in 2025, then grew by 0 bps to 87.28% in 2026.
- The last three Gross Margin figures came in at 87.28% (Q1 2026), 87.24% (Q4 2025), and 85.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 86.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.41% |
| Mar 31, 2026 | 87.28% |
| Dec 31, 2025 | 87.24% |
| Sep 30, 2025 | 85.22% |
| Jun 30, 2025 | 83.37% |
| Mar 31, 2025 | 85.48% |
| Dec 31, 2024 | 84.23% |
| Sep 30, 2024 | 74.95% |
| Jun 30, 2024 | 83.79% |
| Mar 31, 2024 | 85.31% |
| Dec 31, 2023 | 82.95% |
| Sep 30, 2023 | 83.03% |
| Jun 30, 2023 | 80.12% |
| Mar 31, 2023 | 83.98% |
| Dec 31, 2022 | 81.02% |
| Sep 30, 2022 | 82.30% |
| Jun 30, 2022 | 80.99% |
| Mar 31, 2022 | 71.58% |
| Dec 31, 2021 | 77.19% |
| Sep 30, 2021 | 70.89% |